Cargando…

Randomized Mechlorethamine/Chlormethine Induced Dermatitis Assessment Study (MIDAS) Establishes Benefit of Topical Triamcinolone 0.1% Ointment Cotreatment in Mycosis Fungoides

INTRODUCTION: Treatment of early-stage mycosis fungoides (MF) requires safe, skin-directed therapies. Medication side effects can lead to underutilization of effective therapies. The objective of this study was to assess the use of topical triamcinolone 0.1% ointment as a means of reducing contact d...

Descripción completa

Detalles Bibliográficos
Autores principales: Alexander-Savino, Carolina V., Chung, Catherine G., Gilmore, Elaine S., Carroll, Sean M., Poligone, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940998/
https://www.ncbi.nlm.nih.gov/pubmed/35122614
http://dx.doi.org/10.1007/s13555-022-00681-6
_version_ 1784673017185435648
author Alexander-Savino, Carolina V.
Chung, Catherine G.
Gilmore, Elaine S.
Carroll, Sean M.
Poligone, Brian
author_facet Alexander-Savino, Carolina V.
Chung, Catherine G.
Gilmore, Elaine S.
Carroll, Sean M.
Poligone, Brian
author_sort Alexander-Savino, Carolina V.
collection PubMed
description INTRODUCTION: Treatment of early-stage mycosis fungoides (MF) requires safe, skin-directed therapies. Medication side effects can lead to underutilization of effective therapies. The objective of this study was to assess the use of topical triamcinolone 0.1% ointment as a means of reducing contact dermatitis associated with topical mechlorethamine/chlormethine gel for the treatment of MF. METHODS: This prospective, randomized, open-label study evaluated 28 adults with mycosis fungoides who were eligible for treatment with topical mechlorethamine/chlormethine gel from December 17, 2017 to December 23, 2020. Patients were treated for 4 months with clinical follow-up through 12 months. Patients had half of their lesions also treated with topical triamcinolone 0.1% ointment (while the other half were treated with mechlorethamine/chlormethine alone). The study was self-controlled with separate lesions in the same patient receiving each treatment arm. Treatment arms were determined by the flip of a coin. RESULTS: Twenty-eight patients enrolled (17 men (61%) and 11 women (39%)). Demographics included 25 White, 2 African Americans, and 1 Asian patient. Twenty-five completed the 12-month follow-up. Triamcinolone 0.1% ointment led to increased tolerability of mechlorethamine/chlormethine gel but did not change the efficacy of mechlorethamine/chlormethine. There was a statistically significant 50% decrease in dermatitis (SCORD score) at month 2 in the triamcinolone-treated arm. CONCLUSIONS: Topical triamcinolone ointment is a helpful adjuvant therapy when treating patients with topical mechlorethamine/chlormethine gel. It diminishes inflammation and does not reduce efficacy. The peak incidence of dermatitis in the study occurred in the second and third months. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT03380026. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13555-022-00681-6.
format Online
Article
Text
id pubmed-8940998
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-89409982022-04-08 Randomized Mechlorethamine/Chlormethine Induced Dermatitis Assessment Study (MIDAS) Establishes Benefit of Topical Triamcinolone 0.1% Ointment Cotreatment in Mycosis Fungoides Alexander-Savino, Carolina V. Chung, Catherine G. Gilmore, Elaine S. Carroll, Sean M. Poligone, Brian Dermatol Ther (Heidelb) Original Research INTRODUCTION: Treatment of early-stage mycosis fungoides (MF) requires safe, skin-directed therapies. Medication side effects can lead to underutilization of effective therapies. The objective of this study was to assess the use of topical triamcinolone 0.1% ointment as a means of reducing contact dermatitis associated with topical mechlorethamine/chlormethine gel for the treatment of MF. METHODS: This prospective, randomized, open-label study evaluated 28 adults with mycosis fungoides who were eligible for treatment with topical mechlorethamine/chlormethine gel from December 17, 2017 to December 23, 2020. Patients were treated for 4 months with clinical follow-up through 12 months. Patients had half of their lesions also treated with topical triamcinolone 0.1% ointment (while the other half were treated with mechlorethamine/chlormethine alone). The study was self-controlled with separate lesions in the same patient receiving each treatment arm. Treatment arms were determined by the flip of a coin. RESULTS: Twenty-eight patients enrolled (17 men (61%) and 11 women (39%)). Demographics included 25 White, 2 African Americans, and 1 Asian patient. Twenty-five completed the 12-month follow-up. Triamcinolone 0.1% ointment led to increased tolerability of mechlorethamine/chlormethine gel but did not change the efficacy of mechlorethamine/chlormethine. There was a statistically significant 50% decrease in dermatitis (SCORD score) at month 2 in the triamcinolone-treated arm. CONCLUSIONS: Topical triamcinolone ointment is a helpful adjuvant therapy when treating patients with topical mechlorethamine/chlormethine gel. It diminishes inflammation and does not reduce efficacy. The peak incidence of dermatitis in the study occurred in the second and third months. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT03380026. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13555-022-00681-6. Springer Healthcare 2022-02-05 /pmc/articles/PMC8940998/ /pubmed/35122614 http://dx.doi.org/10.1007/s13555-022-00681-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Alexander-Savino, Carolina V.
Chung, Catherine G.
Gilmore, Elaine S.
Carroll, Sean M.
Poligone, Brian
Randomized Mechlorethamine/Chlormethine Induced Dermatitis Assessment Study (MIDAS) Establishes Benefit of Topical Triamcinolone 0.1% Ointment Cotreatment in Mycosis Fungoides
title Randomized Mechlorethamine/Chlormethine Induced Dermatitis Assessment Study (MIDAS) Establishes Benefit of Topical Triamcinolone 0.1% Ointment Cotreatment in Mycosis Fungoides
title_full Randomized Mechlorethamine/Chlormethine Induced Dermatitis Assessment Study (MIDAS) Establishes Benefit of Topical Triamcinolone 0.1% Ointment Cotreatment in Mycosis Fungoides
title_fullStr Randomized Mechlorethamine/Chlormethine Induced Dermatitis Assessment Study (MIDAS) Establishes Benefit of Topical Triamcinolone 0.1% Ointment Cotreatment in Mycosis Fungoides
title_full_unstemmed Randomized Mechlorethamine/Chlormethine Induced Dermatitis Assessment Study (MIDAS) Establishes Benefit of Topical Triamcinolone 0.1% Ointment Cotreatment in Mycosis Fungoides
title_short Randomized Mechlorethamine/Chlormethine Induced Dermatitis Assessment Study (MIDAS) Establishes Benefit of Topical Triamcinolone 0.1% Ointment Cotreatment in Mycosis Fungoides
title_sort randomized mechlorethamine/chlormethine induced dermatitis assessment study (midas) establishes benefit of topical triamcinolone 0.1% ointment cotreatment in mycosis fungoides
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940998/
https://www.ncbi.nlm.nih.gov/pubmed/35122614
http://dx.doi.org/10.1007/s13555-022-00681-6
work_keys_str_mv AT alexandersavinocarolinav randomizedmechlorethaminechlormethineinduceddermatitisassessmentstudymidasestablishesbenefitoftopicaltriamcinolone01ointmentcotreatmentinmycosisfungoides
AT chungcatherineg randomizedmechlorethaminechlormethineinduceddermatitisassessmentstudymidasestablishesbenefitoftopicaltriamcinolone01ointmentcotreatmentinmycosisfungoides
AT gilmoreelaines randomizedmechlorethaminechlormethineinduceddermatitisassessmentstudymidasestablishesbenefitoftopicaltriamcinolone01ointmentcotreatmentinmycosisfungoides
AT carrollseanm randomizedmechlorethaminechlormethineinduceddermatitisassessmentstudymidasestablishesbenefitoftopicaltriamcinolone01ointmentcotreatmentinmycosisfungoides
AT poligonebrian randomizedmechlorethaminechlormethineinduceddermatitisassessmentstudymidasestablishesbenefitoftopicaltriamcinolone01ointmentcotreatmentinmycosisfungoides